ArticleBlood advances2022

Hard-wired biases in trials: maintenance azacitidine in patients with acute myeloid leukemia and framework for future trials.

Timothée Olivier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.